<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03914534</url>
  </required_header>
  <id_info>
    <org_study_id>Versión 1- BIO 088</org_study_id>
    <nct_id>NCT03914534</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Sodium Divalproate Tablets 500 mg</brief_title>
  <official_title>Bioequivalence Study of Sodium Divalproate Tablets 500 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tecnoquimicas</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tecnoquimicas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the bioequivalence of two valproic acid
      formulations through the estimation of valproic acid in plasma samples, according to Food and
      Drugs Administration (FDA), World Health Organization (WHO) and Colombian National Vigilance
      Institute for Drugs and Food (INVIMA) guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single-center, open-label, four-period, two-treatment, two-sequence,
      randomized, single-dose, crossover study. 30 healthy adults will be randomized to receive a
      single dose (500 mg) of the test formulation of valproic acid and reference formulation of
      valproic acid separately in each treatment period. There will be two treatment sequences (AB,
      BA) and a 7 day washout between the two treatment periods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Actual">February 12, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(AUC) Area Under the Curve 0-48</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Formulation of Valproic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valproic Acid tablets 500 mg Single dose administered in dosing period 1 or 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Formulation of Valproic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valcote tablets 500 mg Single dose administered in dosing period 1 or 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid 500 MG</intervention_name>
    <description>Administration of 500 mg of Valproic Acid</description>
    <arm_group_label>Test Formulation of Valproic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valcote 500 mg</intervention_name>
    <description>Administration of 500 mg of Valproic Acid</description>
    <arm_group_label>Reference Formulation of Valproic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Women from 18 to 50 years old

          -  Diagnosed as healthy after a clinical examination

          -  BMI from 18 to 30 kg/m2

          -  Not smoking for at least 3 months

          -  To sign the informed consent

          -  Not having participated in a similar study for at least 4 months

        Exclusion Criteria:

          -  Renal, cardiac immunological, dermatological, endocrine, gastrointestinal,
             neurological or psychiatric condition

          -  Hematologic disorders, specially anemia and polycythemia

          -  Permanent or temporal pharmacological therapy, prescribed or not

          -  Smoking for the last 3 months

          -  Alcohol drinker more than once a week

          -  Drug abuse

          -  Drug hypersensitivity

          -  Angioedema or anaphylaxis history

          -  Pregnancy or breast-feeding

          -  HIV o Hepatitis B diagnosed

          -  Blood donor in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universidad de la Sabana</name>
      <address>
        <city>Chía</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

